APA (7th ed.) Citation

Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., Shore, N. D., de Souza, P., . . . Saad, F. (2014). Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European urology, 66(5), 815-825. https://doi.org/10.1016/j.eururo.2014.02.056

Chicago Style (17th ed.) Citation

Rathkopf, Dana E., et al. "Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)." European Urology 66, no. 5 (2014): 815-825. https://doi.org/10.1016/j.eururo.2014.02.056.

MLA (9th ed.) Citation

Rathkopf, Dana E., et al. "Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)." European Urology, vol. 66, no. 5, 2014, pp. 815-825, https://doi.org/10.1016/j.eururo.2014.02.056.